Drugs / HB0045
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06056323 | Jul 2023 → Sep 2025 | cancer | Shanghai Huaota Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB0045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06056323 ↗ |
| Modality | Monoclonal antibody | “fixed dose combination of two antibodies targeting two different epitopes (N-terminal and catalytic site) of CD73” NCT06056323 ↗ |
| Route | Intravenous | “HB0045 IV every 3 weeks (q3w)” NCT06056323 ↗ |